Braskem Pref ADR
BAK
Braskem Pref ADR (BAK) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| JP Morgan | Downgraded | Overweight → Neutral | — | Jun 30, 2026 |
| Citigroup | Downgraded | Neutral → Sell | — | Jun 26, 2026 |
| UBS | Downgraded | Buy → Neutral | $3.80 from $5.10 | Sep 26, 2025 |
| JP Morgan | Maintained | Neutral | $5.00 from $6.00 | Aug 27, 2025 |
| UBS | Upgraded | Neutral → Buy | $10.00 from $7.70 | Sep 18, 2024 |
| JP Morgan | Maintained | Neutral | $9.50 from $10.00 | Sep 10, 2024 |
| Citigroup | Upgraded | Neutral → Buy | — | Aug 20, 2024 |
| JP Morgan | Maintained | Neutral | $10.00 from $11.00 | May 24, 2024 |
| JP Morgan | Downgraded | Overweight → Neutral | $11.00 from $11.50 | Jul 5, 2023 |
| Scotiabank | Upgraded | Sector Perform → Sector Outperform | $16.75 | May 8, 2023 |
Frequently asked questions
What is the latest analyst rating on BAK?
On Jun 30, 2026, JP Morgan downgraded Braskem Pref ADR to Neutral.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.